Penetrance of inherited medullary thyroid carcinoma and genotype-phenotype correlation in a large multiple endocrine neoplasia type 2A family with C634Y RET mutation

Endocrine Pathology

Volumn 14, Issue 1, 2003, Pages 72-80

  González Yebra, Beatriz ^b,c   Medrano, María Elena ^a   Mantilla, Alejandra ^a   Palma, Virginia ^b   Colin, Carmen ^b   Hernández, Dulce María ^b   Tapia, José ^c   Dawson, Brian ^d   Salcedo, Mauricio ^b  

^a HOSPITAL DE ONCOLOGÍA   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Medullary thyroid carcinoma; Multiple endocrine neoplasia type 2A; Pheochromocytoma; RET mutation

Indexed keywords

CALCITONIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CALCITONIN BLOOD LEVEL; CELL HYPERPLASIA; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; GERM LINE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERPARATHYROIDISM; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PEDIGREE; PENETRANCE; PHENOTYPE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

EID: 0037515620     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1385/EP:14:1:71     Document Type: Article

References (38)

1. Schimke RN. Genetic aspects of multiple endocrine neoplasia. Annu Rev Med 35:25-31, 1984.
2. Farndon JR, Leight GS, Dilley WG, et al. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg 73:278-281, 1986.
3. Feldman GL, Edmonds MW, Ainsworth PJ, et al. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to RET V804M (GTG→ATG) mutation. Surgery 128:93-98, 2000.
4. van Heyningen V. One gene - four syndromes. Nature 367:319,320, 1994.
5. Donis-Keller H. The RET proto-oncogene and cancer. J Int Med 238:319-325, 1995.
6. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN2A and FMTC. Hum Mol Genet 7:851-856, 1993.
7. Mulligan LM, Eng C, Healey CS, et al. Specific Mutations of the RET proto-oncogene are related to disease phenotype in MEN2A and FMTC. Nat Genet 6: 70-74, 1994.
8. Mulligan LM, Marsh DJ, Robinson BG, et al. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the RET mutation consortium. J Int Med 238:343-346, 1995.
9. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET Mutation Consortium analysis. JAMA 276:1575-1579, 1996.
10. Bolino A, Schuffenecker I, Luo Y, et al. RET mutations in exons 13 and 14 of FMTC patients. Oncogene 10:2415-2419, 1995.
11. Eng C, Smith DP, Mulligan LM, et al. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 10:509-513, 1995.
12. Sire NP, Murat A, Rohmer V, et al. Familial medullary thyroid carcinomas with non-cysteine RET mutations: phenotype-genotype relationship in a large series of patients. J Clin Endocrinol Metab 3746-3753, 2001.
13. Berndt I, Reuter M, Saller B, et al. A new hot spot for mutations in the RET proto-oncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 83:770-774, 1998.
14. Shuffenecker I, Billaud M, Calender A, et al. RET proto-oncogene mutations in French MEN2A and FMTC families. Hum Mol Genet 3:1939-1943, 1994.
15. Raue KF, Hoppener W, Frilling A, et al. Mutations of the RET protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. J Clin Endocrinol Metab 81:1780-1783, 1996.
16. Raue KF, Kratt T, Hoppner W, Buhr H, Ziegler R, Raue F. Diagnosis and management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 - relevance of specific mutations in the RET proto-oncogene. Eur J Endocrinol 135:222-225, 1996.
17. Karga HL, Karayianni MK, Linos DA, Tseleni SC, Karaiskos KD, Papapetrou P. Germline mutations analysis in families with multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma. Eur J Endocrinol 139:410-415, 1998.
18. Schuffenecker I, Virally-Monod M, Brohet R, et al. Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. J Clin Endocrinol Metab 83:487-491, 1998.
19. Moers AMJ, Ladsvater RM, Schaap C, et al. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family. Am J Med 101:635-641, 1996.
20. Halling CK, Bufill JA, Cotter M, et al. Age-related disease penetrance in a large medullary thyroid cancer family with a codon 609 RET gene mutation. Mol Diagn 2:277-286, 1997.
21. Chierafi E, Chiarella R, Crocetti U, et al. A large family with hereditary MTC: role of RET genetic analysis in differential diagnosis between MEN 2A and FMTC. Horm Metab Res 33:52-56, 2001.
22. Siggelkow H, Melzer A, Nolte W, Karsten K, Höppner W, Hüffner M. Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the RET proto-oncogene demonstrating low grade of malignancy. Eur J Endocrinol 144:467-473, 2001.
23. Dymling JF, Ljumberg O, Hillyard CJ, Greenberg PB, Evans IMA, MacIntyre I. Whisky: a new provocative test for calcitonin secretion. Acta Endocrinol 82:500-509, 1976.
24. Cohen SL, McIntyre I, Grahame-Smith D, Walker JF. Alcohol-stimulated calcitonin release in medullary carcinoma of the thyroid. Lancet ii:1172, 1173, 1973.
25. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a Cold Spring Harbor laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
26. Komminoth P, Kunz E, Hiort O, et al. Detection of RET proto-oncogene point mutations in paraffin-embedded pheochromocyroma specimens by nonradioactive single strand conformation polymorphism analysis and direct sequencing. Am J Pathol 145:922-929, 1994.
27. Siegelman M, Mohabeer A, Fahey TJ III, et al. Rapid nonradioactive screening for mutations in exon 10, 11 and 16 of the RET proto-oncogene associated with inherited medullary thyroid carcinoma. Clin Chem 43:453-457, 1997.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958.
29. Easton DF, Ponder MA, Cummings T, et al. The Cancer Research Campaign Medullary Thyroid Group: the clinical and screening age-at-onset distribution for the MEN-2 syndrome. Am J Hum Genet 44:208-215, 1989.
30. Machens A, Gimm O, Hinze R, et al. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab 86:1104-1109, 2001.
31. Lairmore TC, Northon JA. Genetics of the multiple endocrine neoplasia (MEN) type 2 syndromes. Am J Surg 173:37-41, 1997.
32. Wells SA, Donis-Keller H. Current perspectives on the diagnosis and management of patients with multiple endocrine neoplasia type 2 syndromes. Endocrinol Metab Clin North Am 23:215-228, 1994.
33. Heshmati HM, Gharib H, van Heerden JA, Sizemore GW. Advances and controversies in the diagnosis and management of medullary thyroid carcinoma. Am J Med 103:60-69, 1997.
34. Wells SA Jr, Chi DD, Toshima K, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 220:237-250, 1994.
35. Gill JR, Reyes-Mujica M, Iyengar S, et al. Early presentation of metastatic medullary carcinoma in multiple endocrine neoplasia type IIA: implications for therapy. J Pediatr 129:459-464, 1996.
36. van Heurn LWE, Schaap C, Sie G, et al. Predictive DNA testing for multiple endocrine neoplasia type 2: a therapeutic challenge of prophylactic thyroidectomy in very young children. J Pediatr Surg 34:568-571, 1999.
37. Thomas PM, Gagel RF. Advances in genetic screening for multiple endocrine neoplasia type 2 and the implications for management of children at risk. Endocrinologist 4:140-146, 1994.
38. Gagel RF, Cote GJ, Bugalho MJGM, et al. Clinical use of molecular information in the management of multiple endocrine neoplasia type 2 A. J Int Med 238:333-341, 1995.